Change in sense of smell · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
1 finding from 1 review
Generic quality of life measures · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Presence of parosmia · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse outcomes · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
1 finding from 1 review
Mean number of oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Depot corticosteroids (systemic; 40 mg methylprednisolone IM every 3… showed no clear difference in mean number of oral ulcers compared with placebo (saline IM injection); GRADE not reported.
1 finding from 1 review
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Episode duration associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Pain associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Episode frequency associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Rate of exacerbations requiring systemic corticosteroids · children and adults with predominantly mild to moderate asthma
Summary of findings table ‐ Vitamin D showed no clear difference in proportion of participants with one or more exacerbations treated… compared with placebo (high certainty).
1 finding from 1 review
Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma
Mepolizumab subcutaneous (SC) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).
1 finding from 1 review
Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma
Reslizumab intravenous (IV) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).
1 finding from 1 review
Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma
Reslizumab subcutaneous (SC) showed no clear difference in rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).
1 finding from 1 review
Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma
Benralizumab subcutaneous (SC) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).
1 finding from 1 review
Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma
Mepolizumab intravenous (IV) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).
1 finding from 1 review
Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis
1 finding from 1 review